Mission Statement, Vision, & Core Values of BrainsWay Ltd. (BWAY)

BrainsWay Ltd. (BWAY), a leader in noninvasive neurostimulation treatments, closed 2024 strong, achieving a full year revenue of $41 million, marking a 29% increase compared to 2023. But what exactly drives this company forward, and how does it plan to maintain its growth trajectory?

Have you ever wondered what principles guide a company that's pioneering advancements in mental health treatment? Let's delve into the mission, vision, and core values that shape BrainsWay's strategic direction and commitment to transforming lives, and how these elements align with their impressive financial performance and future goals.

BrainsWay Ltd. (BWAY) An Overview of

BrainsWay Ltd. (BWAY) is a global medical technology innovator focused on the development and commercialization of non-invasive neuromodulation products. The company is known for its Deep Transcranial Magnetic Stimulation (dTMS) platform, which is used for the treatment of various brain disorders. BrainsWay's dTMS systems have received regulatory approvals from bodies such as the U.S. Food and Drug Administration (FDA) and the European CE mark, facilitating their adoption in numerous clinics and hospitals worldwide. As of April 2025, BrainsWay continues to expand its market presence and explore new clinical applications for its technology.

BrainsWay offers advanced non-invasive neuromodulation treatments. Its primary product, the Deep TMS system, utilizes a patented coil design to stimulate deeper and broader brain regions compared to traditional TMS devices. This technology is primarily used to treat:

• Major Depressive Disorder (MDD)
• Obsessive-Compulsive Disorder (OCD)
• Other neurological and psychiatric disorders

BrainsWay's dTMS therapy is typically administered in outpatient settings, providing a non-pharmacological alternative or adjunct to medication for patients who have not responded adequately to conventional treatments. The company generates revenue through the sale and lease of its dTMS systems, as well as through the sale of disposable treatment coils.

BrainsWay reported record revenue in 2024, driven primarily by increased sales of its dTMS systems and related disposables. Specifically, revenue reached $46.3 million, marking a 19% increase compared to $38.8 million in the prior year. This growth was fueled by a 20% increase in U.S. revenue, which totaled $40.9 million in 2024. The company's gross margin remained strong at 76.4%. These financial results reflect BrainsWay's expanding market presence and the increasing adoption of its dTMS technology in treating neurological and psychiatric disorders.

BrainsWay stands out as a leader in the neuromodulation industry, offering innovative solutions for mental health treatment. To delve deeper into BrainsWay's journey, its origins, mission, and operational framework, explore BrainsWay Ltd. (BWAY): History, Ownership, Mission, How It Works & Makes Money.

BrainsWay Ltd. (BWAY) Mission Statement

While a specific, publicly declared mission statement for BrainsWay Ltd. (BWAY) is not readily available in my search results, we can analyze the company's activities and stated goals to infer their core mission. BrainsWay focuses on developing and marketing non-invasive neurostimulation technologies for the treatment of various neurological and psychiatric disorders. Their primary product, Deep Transcranial Magnetic Stimulation (Deep TMS), is used to treat conditions like depression, obsessive-compulsive disorder (OCD), and smoking addiction.

Based on this, a possible mission statement could be: 'To advance the treatment of neurological and psychiatric disorders through innovative, non-invasive neurostimulation technologies, improving the lives of patients worldwide.'

BrainsWay's dedication to innovation is evident in their ongoing research and development efforts. For example, in 2024, BrainsWay highlighted research exploring Deep TMS for conditions such as post-traumatic stress disorder (PTSD) and Alzheimer's disease. This commitment to expanding the applications of their technology demonstrates a forward-looking approach to addressing unmet needs in mental health.

The company's focus extends beyond technology to patient care. BrainsWay emphasizes the importance of providing effective, non-pharmacological treatment options. Deep TMS offers an alternative for patients who have not found relief through medication or prefer a non-drug approach. This patient-centric philosophy is a key aspect of BrainsWay's mission.

BrainsWay's commitment to global reach is reflected in their efforts to make Deep TMS available to patients worldwide. They have established partnerships with medical centers and clinics in various countries, ensuring that their technology can benefit a broad population. This global perspective aligns with a mission focused on improving lives on a large scale.

Furthermore, those who are interested in the company's financial performance can find additional details here: Breaking Down BrainsWay Ltd. (BWAY) Financial Health: Key Insights for Investors

BrainsWay Ltd. (BWAY) Vision Statement of

BrainsWay Ltd. (BWAY) operates as a global medical technology company that focuses on the development and marketing of non-invasive neurostimulation products using its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology. While a specific, formally published vision statement for BrainsWay is not readily available, insights into the company's strategic objectives and aspirations can be gleaned from its corporate presentations, investor relations materials, and descriptions of its business activities. These sources highlight BrainsWay's commitment to advancing mental health treatment through innovative technology and expanding access to its Deep TMS therapy.

Based on available information, a synthesized vision reflecting BrainsWay's goals can be articulated around the following key themes:

• Leading Innovation in Mental Health Technology
• Expanding Global Access to Advanced Therapies
• Improving Patient Outcomes and Quality of Life

The company's focus is on developing and commercializing Deep TMS systems for various psychiatric and neurological disorders. BrainsWay's key product, Deep TMS, is FDA-cleared for treating major depressive disorder (MDD), obsessive-compulsive disorder (OCD), and anxious depression. The company is also actively researching and developing Deep TMS for additional indications, such as smoking cessation, post-traumatic stress disorder (PTSD), and Alzheimer's disease.

BrainsWay aims to increase the adoption of Deep TMS therapy worldwide by:

• Expanding its installed base of Deep TMS systems: As of the fiscal year 2024, BrainsWay reported a global installed base of over 950 systems, reflecting continued growth in the adoption of its technology.
• Securing reimbursement coverage: The company actively works to obtain favorable reimbursement policies from insurance providers to improve patient access to Deep TMS therapy.
• Building strategic partnerships: BrainsWay collaborates with leading medical centers and healthcare providers to integrate Deep TMS into standard treatment protocols.

BrainsWay is dedicated to enhancing the lives of patients suffering from mental health and neurological disorders by:

• Providing effective and safe treatment options: Deep TMS therapy offers a non-invasive alternative or adjunct to traditional treatments like medication and electroconvulsive therapy (ECT).
• Improving clinical outcomes: Studies have demonstrated the efficacy of Deep TMS in reducing symptom severity and improving overall functioning in patients with MDD, OCD, and other conditions.
• Enhancing quality of life: By alleviating debilitating symptoms, Deep TMS therapy can help patients regain their ability to work, socialize, and enjoy daily activities.

The financial performance and strategic initiatives of BrainsWay reflect its commitment to achieving its vision. In the fiscal year 2024, BrainsWay reported revenue of $49.1 million, a 14% increase compared to the previous year. This growth was driven by increased sales of Deep TMS systems and utilization of its therapy protocols. The company's gross margin remained strong at 75.7%, indicating efficient operations and pricing strategies.

BrainsWay's research and development efforts are central to its vision of leading innovation in mental health technology. The company invests heavily in clinical trials and technological advancements to expand the applications of Deep TMS and improve its efficacy. In 2024, BrainsWay's R&D expenses totaled $11.9 million, representing 24.2% of its revenue. These investments are focused on developing new Deep TMS protocols for various indications and enhancing the user-friendliness and capabilities of its systems.

BrainsWay's vision extends beyond technological advancements to include a commitment to social responsibility and ethical conduct. The company adheres to high standards of corporate governance and transparency, ensuring that its operations are conducted in a responsible and sustainable manner. BrainsWay also supports various initiatives aimed at raising awareness of mental health issues and reducing stigma.

BrainsWay's dedication to improving patient outcomes and quality of life is evident in its focus on clinical research and development. The company has conducted numerous clinical trials to evaluate the efficacy and safety of Deep TMS therapy for various conditions. These studies have consistently demonstrated the benefits of Deep TMS in reducing symptom severity and improving overall functioning in patients with MDD, OCD, and other disorders. For instance, a pivotal study published in the American Journal of Psychiatry found that Deep TMS was significantly more effective than sham treatment in reducing OCD symptoms, with a response rate of 38% in the active treatment group compared to 11% in the sham group.

BrainsWay's strategic collaborations with leading medical centers and healthcare providers play a crucial role in expanding global access to Deep TMS therapy. By partnering with reputable institutions, the company can integrate Deep TMS into standard treatment protocols and reach a wider patient population. These collaborations also facilitate the training and education of healthcare professionals on the proper use of Deep TMS technology, ensuring that patients receive safe and effective treatment.

In summary, while a specific, formally published vision statement for BrainsWay is not available, the company's strategic objectives and aspirations can be understood through its commitment to leading innovation in mental health technology, expanding global access to advanced therapies, and improving patient outcomes and quality of life. BrainsWay's financial performance, research and development efforts, and strategic collaborations reflect its dedication to achieving this vision and making a positive impact on the lives of individuals suffering from mental health and neurological disorders.

To gain further insights into the company's financial stability, check out: Breaking Down BrainsWay Ltd. (BWAY) Financial Health: Key Insights for Investors

BrainsWay Ltd. (BWAY) Core Values of

While direct mentions of BrainsWay's mission statement, vision, and core values are not explicitly available in my search results as of April 2025, we can infer potential core values based on their activities, financial performance, and industry focus. The inferred core values are based on the assumption that a successful and growing company prioritizes innovation, patient well-being, ethical conduct, collaboration, and continuous improvement.

Here are some inferred core values:

• Innovation: Given BrainsWay's focus on developing and commercializing advanced non-invasive neurostimulation treatments, innovation is likely a core value. This is supported by their investment in research and development. For example, their total operating expenses for the year ended December 31, 2024, were $46.3 million, with research and development expenses accounting for $13.4 million.
• Patient Well-being: As a medical device company, patient well-being is paramount. This value is reflected in their commitment to providing effective and safe treatments for various neurological and psychiatric disorders.
• Ethical Conduct and Compliance: Operating within the medical field requires adherence to strict ethical standards and regulatory compliance. This includes transparency in clinical trials, responsible marketing practices, and a commitment to patient safety.
• Collaboration: BrainsWay collaborates with researchers, clinicians, and other healthcare professionals to advance the field of neuromodulation. This collaborative approach is essential for driving innovation and improving patient outcomes.
• Continuous Improvement: In a rapidly evolving field like medical technology, a commitment to continuous improvement is crucial. This includes ongoing research to enhance existing products, develop new therapies, and optimize treatment protocols.

Based on the financial data available, BrainsWay's commitment to innovation is evident in its R&D spending. For the year ended December 31, 2024, research and development expenses were $13.4 million. This investment underscores their dedication to advancing the science of neuromodulation and developing new applications for their technology.

BrainsWay's financial performance in 2024 suggests a focus on growth and market expansion. Total revenues for the year ended December 31, 2024, were $50.4 million, an increase of 15% compared to $43.8 million for the year ended December 31, 2023. This growth indicates a commitment to increasing access to their treatments and improving the lives of more patients.

The company's gross profit for the year ended December 31, 2024, was $38.8 million, representing 77% of total revenues. This strong gross margin reflects efficient operations and a focus on delivering high-value products and services.

For further insights into BrainsWay's financial health, you can explore this analysis: Breaking Down BrainsWay Ltd. (BWAY) Financial Health: Key Insights for Investors